Management of Partial IgA Deficiency

Diagnosis and Risk Assessment

Patients with partial IgA deficiency have increased susceptibility to recurrent sinopulmonary infections, particularly when associated with impaired specific antibody responses to pneumococcal polysaccharides, according to the American Academy of Allergy, Asthma, and Immunology 1
Atopic disease occurs in approximately 18-19% of IgA-deficient patients, and allergic inflammation predisposes to secondary respiratory tract infections, especially sinusitis and otitis media, as noted by the American Academy of Allergy, Asthma, and Immunology 1
Some patients with partial IgA deficiency may progress to complete selective IgA deficiency or develop common variable immunodeficiency (CVID) later in life, with a family history of SIGAD or CVID existing in 20-25% of affected individuals, according to the American Academy of Allergy, Asthma, and Immunology 1

Aggressive antimicrobial therapy for acute infections with longer courses than immunocompetent patients is recommended for patients with recurrent sinopulmonary infections, according to the American Academy of Allergy, Asthma, and Immunology 1
Prophylactic antibiotics (amoxicillin, trimethoprim/sulfamethoxazole, or macrolides) may be considered for patients with recurrent infections, as suggested by the American Academy of Allergy, Asthma, and Immunology and the Infectious Diseases Society of America 1, 2
IgG replacement therapy may be considered for patients with severe phenotype or treatment failure, with a starting dose of 400-600 mg/kg IVIG, adjusted based on clinical response and trough IgG levels, according to the Infectious Diseases Society of America 2

Patients with very low IgA may develop anti-IgA antibodies, creating risk for anaphylactic reactions to blood products, and some centers use IgA-deficient donor products or wash cells before transfusion, as noted by the American Academy of Allergy, Asthma, and Immunology 1
Regular follow-up to monitor for evolution to CVID or development of more severe immunodeficiency is recommended, with reassessment of immune function if clinical status changes, according to the Infectious Diseases Society of America 2